Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Recruiting now · Phase 2

Conditions studied: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

In brief

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Key facts

Study ID

NCT06280508

Run by

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

People needed

40

Starts

2024-03-01

Expected to finish

2028-03-31

Last updated by the study team

2024-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• confirmed intrahepatic cholangiocarcinoma
• with Resectable tumor lesion
• no contraindications to surgery
• with high risk of tumour recurrence
• No prior systemic therapy for intrahepatic cholangiocarcinoma.
• ECOG Performance Status of 0 or 1
• Child-Pugh Class: Grade A

You may not qualify if…

• History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
• Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
• Known genetic or acquired hemorrhage or thrombotic tendency
• Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
• Cardiac clinical symptom or disease that is not well controlled
• Hypertension that can not be well controlled through antihypertensive drugs

Where it is running

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — Guangzhou, China/Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.